• Semaphorin Receptors Antagonize Wnt Signaling

  2026-08-21

  A 2024 bioRxiv preprint reports that Neuropilin and Plexin semaphorin receptors suppress Wnt signaling by promoting proteasome-dependent β-catenin destabilization, independently of primary cilia. The findings identify receptor-specific control points downstream of Dishevelled and suggest that GSK3β/CK1 dependence differs between Neuropilins and Plexins, with implications for interpreting pharmacological Wnt experiments.

• Ciprofloxacin: From Target to Translational Assay

  2026-08-21

  Ciprofloxacin is more than a fluoroquinolone antibiotic benchmark: it can connect bacterial target biology with emerging nanotheranostic assay design. This article explains how to use its molecular mechanism, formulation constraints, and the 2026 ZIF8 study to build more interpretable research workflows.

• BFH772 (VEGFR2 inhibitor): Practical Lab Guide

  2026-08-20

  BFH772 is a selective VEGFR2 inhibitor for controlled studies of VEGFR2-linked signaling and angiogenic phenotypes when an organic-solvent-compatible small molecule is suitable. It should not be used in water-only workflows, treated as a universal kinase inhibitor, or used to infer clinical efficacy without independent validation.

• TAK-242 (Resatorvid): TLR4 Inhibition Guide

  2026-08-20

  TAK-242, also called Resatorvid, is a selective small-molecule inhibitor used to study TLR4 signaling pathway modulation. It suppresses LPS-triggered inflammatory mediators in macrophage assays and reduces collagen deposition in a nickel oxide nanoparticle-treated LX-2 cell model, but these findings do not establish clinical efficacy.

• MK-1775: Reframing Wee1 Checkpoint Studies

  2026-08-19

  A translational framework for using MK-1775 to interrogate Wee1 biology, distinguish cytostasis from cell killing, and design more decision-ready studies in p53-deficient tumor models.

• Naloxone Hydrochloride in Opioid Research

  2026-08-19

  Naloxone hydrochloride is more than a reversal tool: it is a versatile opioid receptor antagonist for separating receptor-dependent effects from withdrawal, stem-cell, immune, and behavioral mechanisms. This practical guide connects reproducible solution handling with assay design inspired by morphine-withdrawal anxiety research.

• Polymer Pen Lithography for 3D SERS Nanoclusters

  2026-08-18

  The reference study presents polymer pen lithography (PPL) as a route to highly ordered three-dimensional gold nanoparticle cluster arrays for surface-enhanced Raman scattering. By combining programmable polyethylenimine patterning with electrostatic nanoparticle assembly, the authors report an enhancement factor of 1.67 × 10^7 and a relative standard deviation below 4.73%, while retaining structural tunability.

• Carbapenemase Gene Transmission in CREC

  2026-08-18

  Chen et al. integrated resistance-gene localization, antimicrobial susceptibility testing, plasmid conjugation, mobile-element profiling, and ERIC-PCR genotyping to examine carbapenem-resistant Enterobacter cloacae across eight teaching hospitals in Guangdong. The findings identify blaNDM−1 as the dominant carbapenemase determinant and show substantial potential for both plasmid-mediated horizontal transfer and clonal dissemination.

• Nanoparticle mRNA Delivery to Reverse Trastuzumab Resistance

  2026-08-17

  Dong et al. developed a tumor-microenvironment-responsive nanoparticle platform for systemic PTEN mRNA delivery in trastuzumab-resistant HER2-positive breast cancer. The approach restored PTEN expression, inhibited PI3K/Akt signaling, and improved the antitumor activity of trastuzumab, while highlighting the formulation and biological barriers that govern therapeutic mRNA delivery.

• Annexin V-FITC/PI Apoptosis Assay Kit Workflow

  2026-08-17

  Use dual Annexin V-FITC and PI staining to separate viable, early apoptotic, and membrane-compromised cells in a rapid workflow. The assay is especially valuable when treatment studies need a phenotypic apoptosis endpoint linked to ROS, mitochondrial, or metabolic measurements.

• Palbociclib Beyond Monocultures: A Translational Playbook

  2026-08-16

  Palbociclib (PD0332991) is more than a selective CDK4/6 inhibitor: it is a mechanistic probe for testing how tumor–stroma interactions reshape cell-cycle dependence, drug response, and resistance. This thought-leadership guide connects the compound’s CDK4/6–Rb–E2F biology with patient-derived gastric cancer assembloids and offers a practical framework for translational breast cancer and renal cell carcinoma research.

• Staurosporine at the ECM–Kinase Interface

  2026-08-15

  A translational framework for using Staurosporine to interrogate how collagen architecture, kinase signaling, apoptosis, and angiogenesis interact in breast cancer models—without mistaking a broad perturbation tool for a single-target therapeutic proxy.

• Angiotensin 1/2 (1-6): From RAS to Translation

  2026-08-14

  Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, offers translational researchers a sequence-defined way to investigate renin-angiotensin system signaling, vascular tone, cardiovascular regulation, renal physiology, and an emerging connection to viral receptor biology.

• SD 169: Selective p38α/β MAPK Inhibitor

  2026-08-14

  SD 169, also called indole-5-carboxamide, is a selective ATP-competitive inhibitor of p38α and p38β MAPKs. Product information positions it for mechanistic studies of inflammatory signaling, type 1 diabetes research, apoptosis assays, and axonal regeneration research.

• Homoharringtonine Workflows for Cancer Biology

  2026-08-13

  Homoharringtonine is a cytotoxic alkaloid that connects protein-synthesis research, leukemia models, and carefully controlled antiviral assays. This guide translates its ribosome-directed activity into practical workflow design, assay controls, and troubleshooting strategies while separating research findings from clinical claims.

15651 records 1/1044 page Next 12345 下5页 Last page